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Localization of lipopolysaccharide 
from Escherichia Coli into human 
atherosclerotic plaque
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Luca Pacini1, Veronica Sorrentino1, Ombretta Martinelli3, Luigi Irace3, Sebastiano Sciarretta1, 
Giacomo Frati1, Daniele Pastori  2 & Francesco Violi2
Experimental studies showed that gut-derived lipopolysaccharide (LPS) is pro-atherogenic, however, 
its relationship with human atherosclerosis is still to be defined. We investigate if gut-derived LPS from 
Escherichia Coli localizes in human carotid plaque and its potential role as pro-inflammatory molecule 
in the atherosclerotic lesion. LPS from Escherichia Coli and Toll-like receptor 4 (TLR4) were studied in 
specimens from carotid and thyroid arteries of 10 patients undergoing endarterectomy and 15 controls 
matched for demographic and clinical characteristics. Blood LPS were significantly higher in patients 
compared to controls. Immunochemistry analysis revealed positivity for antibodies against LPS and 
TLR4 coincidentally with positivity for CD68 only in the atherosclerotic plaque of carotid arteries but not 
in thyroid arteries; the positivity for LPS and TLR4 was greater in the area with activated macrophages. 
LPS concentration similar to that detected in atherosclerotic plaque resulted in a dose-dependent TLR4-
mediated Nox2 up-regulation by human monocytes. These data provide the first evidence that LPS 
from Escherichia Coli localizes in human plaque and may contribute to atherosclerotic damage via TLR4-
mediated oxidative stress.
Recent experimental and clinical studies discovered that intestinal microbiota is implicated in the atherosclerotic 
process1. For example, trimethylamine N-oxide, which stems from microbial conversion of dietary nutrients 
containing choline, phosphatidylcholine and L-carnitine, possesses pro-atherogenic and pro-thrombotic activi-
ties and is associated with cardiovascular risk2. Other products of gut microbiota, such as LPS, which is a major 
component of the outer layer of Gram-negative bacteria, may also be involved in the athero-thrombosis process. 
In the circulation of healthy subjects LPS may be found in a range of concentration of approximately 15–200 pg/
ml3. One mechanism through which LPS enters human circulation is with apolipoprotein B48-containing lipo-
proteins, therefore increasing after a lipid-rich meal4. In addition, LPS may cross gastro-intestinal tube because of 
increased gut permeability due to impaired tight junctions. This phenomenon occurs in several conditions asso-
ciated with atherosclerosis, such as type II diabetes, obesity and hypertension, which may display elevated LPS 
circulating levels5. The pro-atherogenic role of LPS is supported by experiments showing smaller atherosclerotic 
plaque in animals with genetic deletion of TLR46 and acceleration of plaque formation in animals injected with 
LPS7. A hypothetical relationship between LPS and human atherosclerosis has been suggested by a prospective 
study that documented an association between circulating LPS and atherosclerosis burden8. Moreover, LPS may 
contribute to the thrombotic process, even at concentrations found in the human circulation; thus, a recent study 
demonstrated that LPS amplifies the platelet response to common agonists upon interaction with its receptor 
TLR49. However, the impact of gut-derived LPS in human atherosclerotic plaque is still to be clarified. We spec-
ulated that, once reached systemic circulation, LPS might cross endothelial wall eliciting a pro-inflammatory 
response upon cell interaction within the sub-endothelial space.
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Results
Demographic and clinical variables in patients and controls are reported in the Table 1. There were no differ-
ences in terms of age, gender and concomitant anti-atherosclerotic and anti-thrombotic treatment. Compared to 
patients who were complicated by >70% critical stenosis, controls had no signs of carotid atherosclerotic plaque 
by Doppler ultrasonography. Furthermore, neither patients nor controls displayed signs of acute or chronic 
infection.
Circulating levels of LPS (79.0 ± 10.7 vs. 43.5 ± 11.9 pg/ml, p < 0.001) and zonulin (4.5 ± 0.7 vs. 2.2 ± 1.1 ng/
ml, p < 0.001) were significantly higher in patients compared to controls (Table 1). Circulating LPS correlated 
with serum zonulin (r = 0.553, p < 0.05) and soluble TLR4 (r = 0.490, p < 0.05).
Immuno-histochemical analysis revealed the presence of an atheromatous core with foam cells and lympho-
cytes close to the lipid core in all carotid arteries (Fig. 1A). Conversely, thyroid arteries did not disclose any sign 
of atherosclerotic damage (Fig. 1B). Moreover, hematoxylin and eosin staining of the carotid plaque revealed the 
presence of calcium precipitates at the level of the media tunica of carotid artery, which were associated with cho-
lesterol crystals and inflammatory lympho-mononuclear cells. In three serial sections of this area, IHC analysis 
revealed immunoreactivity for antibodies against LPS from Escherichia Coli (EC) (Fig. 1A1), TLR4 (Fig. 1A2) 
and CD68 antibody (Fig. 1A3) in all the carotid samples, while no IHC reactivity was detected in thyroid arteries 
(Fig. 1B1–B3). Serial sections stained with CD68 antibody were also positive for antibodies against LPS (37%) 
and TLR4 (33%) (Fig. 1A1–A3). In the carotid plaque sections, analysis of macrophage morphology showed that, 
in the area positive for LPS and TLR4, macrophages were much bigger (Fig. 2A,B, star) compared to macrophages 
in the area with less reactivity to LPS and TLR4 (Fig. 2A,B, arrow).
As our data lead to hypothesize that LPS, once recognized by inflammatory cells, may behave as a 
pro-inflammatory molecule, we performed in vitro experiments to explore if LPS, at concentration detected 
in the plaque, was biologically active via interaction with TLR4. Concentration of LPS in carotid plaques was 
42.3 ± 8.0 pg/ml and significantly correlated with the corresponding LPS circulating levels (r = 0.668, p < 0.05). 
Thus, we incubated monocytes from healthy subjects and patients with serial concentration of LPS (20–80 pg/
ml) and found that LPS dose-dependently elicited a burst of oxidant species, as shown by a significant increase 
of hydrogen peroxide and conjugated dienes compared to control (Fig. 3, panels A and B and Fig. 4, panels A 
and B) and enhanced formation of oxidized LDL (Fig. 3C). All these effects were already statistically significant 
at 40 pg/ml LPS and blunted by cell incubation with a TLR4 inhibitor; conversely, no changes were detected with 
control peptide (Fig. 3A–C). To examine the mechanism related to LPS-mediated oxidative stress, we focused on 
the potential role of Nox2, which is among the most important cell producer of oxidant species10). Nox2 pertains 
prevalently to the innate immune system where its activity is crucial for bacterial killing10 but it also localizes 
in the artery wall where it is implicated in the athero-thrombotic process11. To assess the activity of Nox2, we 
measured, as previously described, a split-off product released in the medium as soluble Nox2-derived peptide 
(sNox2-dp) upon Nox2 activation11. The in vitro experiments demonstrated that downstream effect of cells incu-
bated with LPS was characterized by a dose-dependent increase of sNox2-dp, an effect inhibited by cell incuba-
tion with TLR4 inhibitor (Fig. 3D). Further support to the role of Nox2 as trigger of LPS-mediated oxidative stress 
was provided by incubating cells with a Nox2 specific inhibitor, which, in fact, blunted the formation of hydrogen 
peroxide, conjugate dienes and oxidized LDL (Fig. 3A–D).
Discussion
The study provides evidence that LPS from Escherichia Coli localizes in human atherosclerotic plaque but not in 
normal artery and may trigger inflammation via interaction with TLR4.
To investigate the relationship between LPS and atherosclerosis, we followed a previously described proce-
dure consisting in examining atherosclerotic specimens from candidates to carotid endarterectomy (CEA)12. 
Carotid specimens displayed positivity for LPS in the area, which was characterized by intense positivity for 
antibody against macrophages. Co-localization of LPS immunostaining with that for an antibody against a spe-
cific macrophage epitope suggests specific LPS binding to macrophages detected in the atherosclerotic lesion; 
in accordance with this, we failed to detect LPS in the extracellular medium. At variance with macrophage-rich 
Controls (n = 15) Patients (n = 10) p
Age 70.7 ± 6.0 73.1 ± 8.9 0.433
Women (%) 26.7 20.0 0.702
Hypertension (%) 100.0 100.0 —
Dyslipidaemia (%) 90 90 —
Diabetes (%) 53.3 30.0 0.414
BMI (Kg/m2) 28.2 ± 2.7 27.1 ± 2.6 0.458
ACE/ARBs (%) 86.7 70.0 0.358
Β-blockers (%) 33.3 10.0 0.345
Antiplatelet drugs (%) 100.0 100.0 —
Statins (%) 100.0 90.0 0.400
Serum LPS (pg/ml) 43.5 ± 11.9 79.0 ± 10.7 <0.001
Serum zonulin (ng/ml) 2.2 ± 1.1 4.5 ± 0.7 <0.001
Table 1. Clinical and laboratory characteristics of patients and controls.
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Figure 1. Immune-histochemical (IHC) analyses of LPS, TLR4 and CD68 in carotid plaques and superior 
thyroid arteries. Immunostaining for LPS and TLR4 and cell phenotype in carotid atherosclerotic plaque (A) 
and thyroid artery (B). Serial sections (2 μm) were prepared as described in Online Methods and stained with 
hematoxylin and eosin. The presence of the antigen recognized by the primary antibody is indicated by a brown 
substrate. IHC analysis revealed immunoreactivity for antibodies against LPS from Escherichia Coli (EC) (A1, 
10X), TLR4 (A2, 10X) and CD68 (A3, 10X) in three serial sections of carotid plaque particularly in the area 
associated with necrotic lipid core (asterisk). Immunostaining for anti-LPS, anti-TLR4 and anti-CD68 reveals 
no reactivity in thyroid arteries (B1–B3, 10X). Negative control, with a rabbit preimmune serum, in the area of 
the plaque near the lipid necrotic core and thyroid artery section (A4 and B4, 10X). A view of Panels A1–A3 
and Panels B1–B3 at higher magnification was reported (40X).
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atherosclerotic lesion, normal arteries were negative for antibodies against either LPS or CD68, indicating that 
in absence of macrophages LPS is not implicated in atherosclerotic process unless macrophages have already 
infiltrated the artery wall.
Morphological changes are hallmarks of the macrophage inflammatory response. Formation of lamellipo-
dia and filopodia, that are important for attachment to the extracellular matrix and ensuing cell adhesion and 
migration to inflammatory sites as well as cell size are markers of macrophage activation13. In this context, it 
is of particular interest the fact that positivity for LPS and TLR4 were detected essentially in atherosclerotic 
lesion characterized by activated macrophages, providing indirect evidence that LPS might act as stimulus for 
macrophage activation. This could occur via interaction with TLR4, which is a specific receptor for LPS on mac-
rophage surface14 and was indeed detected by immunostaining in the same area where positivity for LPS and 
activated macrophages was evidenced. To corroborate this hypothesis, in vitro experiments were performed to 
establish if LPS, in the same range of concentration detected in atherosclerotic plaque, was able to activate human 
monocytes. We found that LPS dose-dependently activated monocyte via TLR4 activation with an intra-signaling 
mechanism involving up-regulation of Nox2, which is among the most important cellular producer of reactive 
oxidant species15. As this downstream effect resulted in formation of oxidized LDL, it could be arguable a role for 
LPS as molecule promoting oxidative stress at site of atherosclerotic lesion.
The study has implications and limitations. The mechanism accounting for LPS translocation from gut micro-
biota to atherosclerotic plaque was not fully addressed by the present study; however, changes in gut permeability 
might be a plausible mechanism as increased serum zonulin, which reflects enhanced gut permeability, signifi-
cantly correlated with blood LPS. This hypothesis needs to be explored by directly analyzing gut permeability in 
Figure 2. Morphological changes of activated macrophages. Immunostaining for LPS (A) and TLR4 (B) in 
carotid plaque revealed that in the area where the immunoreactivity for antibodies against LPS from Escherichia 
Coli (EC) (A) or for antibodies against TLR4 (B) was higher, macrophages CD68 positive showed signs of 
activation (red star). They appeared bigger compared to non-activated macrophages (arrow), which, conversely, 
were detected in the area with a less reactivity to LPS and TLR4 and disclosed typical round shape.
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patients with clinically overt atherosclerosis. We show that LPS from EC across the arterial wall and localizes in 
the atherosclerotic plaque but do not provide a direct evidence that LPS binds to TLR4 and activates macrophages 
in situ; however, our data provide a rationale to assess if lowering serum levels of EC-LPS from gut microbiota 
may be implicated in atherosclerosis progression. In this context Mediterranean diet, which is associated with 
reduced risk of atherosclerotic progression16, may be an interesting nutritional approach as adherence to this diet 
lowers circulating LPS concentration in patients prone to atherosclerotic complications17.
We have recently reported that in patients at risk of cardiovascular events circulating LPS concentration inde-
pendently predicted myocardial infarction, stroke and cardiovascular death during a follow-up of about 3 years17. 
The significant correlation between concentration of LPS in blood and in atherosclerotic plaque provides a poten-
tial interpretation of this report and would suggest blood LPS concentration to be considered for clinical purpose 
as marker of atherosclerosis progression.
In conclusion, the positivity of LPS from EC in human carotid plaque provides further insight in the role of 
gut microbiota in atherosclerotic process and suggests LPS from EC as a novel trigger of the inflammation occur-
ring in atherosclerosis.
Methods
Study design. We performed a cross-sectional study including 10 patients with critical stenosis of carotid 
artery (>70%) undergoing carotid endarterectomy (CEA). Fifteen control patients with a negative Doppler 
ultrasound for carotid plaques were also enrolled. Patients and controls were balanced for age (73.1 ± 8.9 vs. 
70.7 ± 6.0, p = 0.433) sex (percentage of women was 20 vs. 26.7%, p = 0.702) and cardiovascular risk factors. Thus, 
Figure 3. LPS-mediated oxidative stress in monocytes from healthy subjects. Lympho-monocytes from healthy 
subjects (HS; n = 5) were incubated with or without LDL (50 μg/ml) and stimulated with scalar concentrations 
of LPS (20–80 pg/ml) in presence or less of TLR4bp inhibitor (4 μM), Nox2-tat (50 μM) or control peptide (CP) 
(4 μM) for the evaluation of H2O2 production (A), conjugated dienes (B), oxLDL formation (C) and sNox2-dp 
(B) (*p < 0.01, Student’s t-test).
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all patients and controls were hypertensive and treated with antiplatelet drugs, 100% and 90% of patients and 
controls were treated with statins, respectively (p = 0.400). No significant difference in the distribution of diabetes 
was observed (30% of patients vs. 53.3% of controls, p = 0.414).
Cardiovascular risk factors, such as arterial hypertension18 and diabetes19 were defined according to interna-
tional guidelines.
Patients with active cancer, systemic autoimmune of infectious diseases were excluded from the study. 
The study was conformed to the declaration of Helsinki and approved by the Ethical Committee of Sapienza 
University of Rome. All patients recruited gave written informed consent to participate in the study.
Sample acquisition and tissue processing. Human carotid plaques were homogenized immediately 
after chirurgical excision, as previously described20, in 1 ml of phosphate buffer saline (PBS) containing 1% Triton 
X-100 and frozen overnight at −80 °C. The next day, non-dissolved fragments were removed by centrifugation at 
12.000 rpm for 5 min and supernatant collected for biochemical analysis.
As negative control, the superior thyroid artery was obtained from same patients concomitantly to CEA; cross 
section of the superior thyroid artery was deemed necessary for an adequate exposure and dissection of carotid 
arteries.
A blood sample from antecubital vein was taken from patients and controls, who had fasted 12 hours. Blood 
was centrifuged at 300 × g for 10 minutes to obtain serum and stored at −80 °C.
Figure 4. LPS-mediated oxidative stress in monocytes from patients with carotid stenosis. Lympho-
monocytes from patients (HS; n = 4) were incubated with or without LDL (50 μg/ml) and stimulated with 
scalar concentrations of LPS (20–80 pg/ml) in presence or less of TLR4bp inhibitor (4 μM), Nox2-tat (50 μM) 
or control peptide (CP) (4 μM) for the evaluation of H2O2 (A) and conjugated dienes (B) (*p < 0.01, Student’s 
t-test).
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Measurement of Lipopolysaccharide. Lipopolysaccharide (LPS) levels in serum and in homogenates 
of carotid plaques were measured using a commercial ELISA kit (Product No. CSB-E09945h; Cusabio, Wuhan, 
China). Standards of LPS, purified from Escherichia coli, and samples were plated for 2 hours at room temperature 
onto a microplate pre-coated with the antibody specific for LPS. After incubation, samples were read at 450 nm. 
Values were expressed as pg/ml; intra-assay and inter-assay coefficients of variation (CVs) were 8% and 10%, 
respectively.
Measurement of zonulin. Serum levels of zonulin were measured using a commercially ELISA kit 
(Product No. E-EL-H5560 Elabscience, Wuhan, China). Antibody specific for zonulin has been pre-coated onto a 
microplate and 100 µl of standards and patient sera samples were added and incubated 90 minutes at 37 °C. Then, 
a biotinylated detection antibody specific for zonulin and Avidin-Horseradish Peroxidase (HRP) conjugate was 
added to each microplate. The amount of zonulin was measured with a microplate auto-reader at 450 nm. Values 
were expressed as ng/ml. Both intra- and inter-assay CVs were <10%.
Immunohistochemistry analysis. All samples were collected and fixed in 10% neutral buffered formalin, 
dehydrated in ethanol and embedded in paraffin. The sample was cut into 2 μm thick sections using a microtome. 
The slices were dewaxed in xylene, rehydrated through a graded series of ethanol solutions, washed in distilled 
water and PBS. Serial sections were subjected to antigen retrieval procedure by microwaving in 0.01 M sodium 
citrate buffer pH 6.0; endogenous peroxidase activity was blocked by incubation with 3% H2O2 in methanol 
for 15 min. The slices were incubated overnight at 4 °C with the following antibody: anti E. coli LPS antibody 
(1:100) (Product No. ab35654, Abcam, Cambridge, UK); anti-CD68 (Product No. NCL-CD68-KP1, Leica 
Biosystems, Wetzlar, Germany) was used to identify monocytes/macrophages; anti-CD31 antibody (Product 
No. PA0414, Leica Biosystems, Wetzlar, Germany) was used to identify angiogenesis; anti-CD34 antibody 
(Product No. PA0212, Leica Biosystems, Wetzlar, Germany) was used to identify endothelial vessel; anti-CD3 
antibody (Product No. PA0122, Leica Biosystems, Wetzlar, Germany) was used to identify T-cells; anti-CD20 
antibody (Product No. PA0359, Leica Biosystems, Wetzlar, Germany) was used to identify B-cells; TLR4 (1:100) 
(Product No. sc13593, Santa Cruz Biotechnology, Dallas, USA). After washing in PBS, the slices were processed 
as described in the protocol of kit Dako LSAB2 System-HRP (Product No. K0673, Santa Clara, USA). Slices were 
lightly counterstained with Haematoxylin, dehydrated in ethanol, cleared in xylene and mounted. Digital images 
were acquired using a digital System D-Sight (Menarini, Florence, Italy). The percentage of cells positive for LPS 
and TLR4 out of total macrophages (CD68 positive cells) were estimated by averaging positive cells in 3 regions 
using a 40X objective.
In vitro study. Isolation of peripheral blood mononuclear cells (PBMCs). Freshly taken EDTA-blood from 
healthy subjects and patients with carotid stenosis (n = 5, 3 males and 2 females age 44.4 ± 3.2 for healthy subjects 
and n = 5, 5 males age 75.6 ± 5.5 for patients) was diluted with PBS (1:4) and stratified carefully over 10 mL of 
Ficoll-Paque in 50 mL conical tube and then centrifuged at 1660 rpm for 30 minutes at 20 °C in a swinging-bucket 
rotor without brake. The mononuclear cell layer (lymphocytes and monocytes) at the interphase was aspired 
and transferred into a 50 mL conical tube. Finally, the tubes were filled with PBS and cell was washed 2 times by 
centrifugation at 1000 g for 10 minutes. Cells were incubated with Nox2ds-tat (50 µM, Product No. AS63818, 
Anaspec, California, USA) or TLR4bp (4 µM, Product No. NBP2–26244, Novus Biologicals, Colorado, USA) or 
control peptide (CP) (4 µM, Product No. NBP2–26244, Novus Biologicals, Colorado, USA) and added with or 
without serial LPS concentrations (20–80 pg/ml, Product No. L3015, Sigma Aldrich, Saint Louis, USA) in pres-
ence or less of 50 µg/ml of LDL. After 30 min incubation, samples were centrifuged for 3 minutes at 3000 rpm. 
Supernatants were stored at −80 °C for analysis of conjugated dienes, oxidized LDL (ox-LDL), H2O2 and 
sNox2dp.
Conjugated dienes. The standard oxidation assay was performed using a UV/VIS spectrometer (UV1800, AOE 
Instruments (Shanghai) Co., Ltd). Measurement of the 234 nm absorption was read in cell supernatant after stim-
ulation and expressed as micromoles of conjugated dienes.
Hydrogen peroxide and oxidized LDL production. The hydrogen peroxide (H2O2) was evaluated by a 
Colorimetric Detection Kit (Product No. K034, Arbor Assays, Michigan, USA) and expressed as μM. Intra- and 
inter-assay CVs were 2.1% and 3.7% respectively. We measured oxLDL by ELISA commercial Kit (Product No. 
CSB-E07931h Cusabio, China). Values are expressed as mU/ml. Intra- and inter-assay CVs were <8% and <10%, 
respectively.
sNox2dp measurement. Extracellular levels of soluble Nox2-derived peptide (sNox2-dp), a marker of NADPH 
oxidase activation, were detected by ELISA as previously described21. The peptide was recognized by the specific 
monoclonal antibody against the amino acidic sequence (224–268) of the extra membrane portion of Nox2 (cat-
alytic core of NADPH oxidase), which is released in the medium upon cell activation. Values were expressed as 
pg/ml; intra-assay and inter-assay CVs were 5.2% and 6%, respectively.
Statistical analysis. Categorical variables were reported as percentages, continuous variables as means ± stand-
ard deviation (SD). Comparisons between patients undergoing CEA and control patients were made by Student 
t-test (for continuous variables) or chi-square test (for categorical variables). Univariable correlation analysis was 
performed by the Pearson’s correlation coefficient. A value of p < 0.05 was considered as statistically significant. 
All analyses were performed with SPSS V.18.0 (SPSS Inc., Chicago, IL, USA).
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Based on previous works17,22, the minimum sample size was computed with respect to a two-tailed Student 
t test for independent groups, considering 1) relevant difference of LPS levels to be detected between groups 
|δ| ≥ 30 with SDs homogeneous between the groups (SD = 20), and 3) type I error probability α = 0.05 and power 
1-β = 0.90. This resulted in n = 10 for group.
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